Christopher Brophy v. Jiangbo Pharmaceuticals, Inc., 781 F.3d 1296

Background

Jiangbo Pharmaceuticals, a U.S. public company formed via a reverse merger, traded on NASDAQ for under a year (class period) and reported cash balances near or above $100 million in SEC filings.
Plaintiffs (investors) alleged Jiangbo overstated cash and failed to disclose a related-party RMB 200 million (~$31M) transfer to Hilead, a company controlled by chairman Cao.
Elsa Sung served as Jiangbo’s CFO during most of the class period and certified SEC filings and made public statements about the company’s strong cash position; Frazer (auditor) issued an unqualified audit opinion for fiscal year 2010.
After SEC and internal investigations began (late 2010–early 2011), Sung resigned effective March 31, 2011; Frazer withdrew from reappointment consideration; trading fell precipitously and disclosures in May 2011 revealed the SEC investigation and a loan default.
Plaintiffs sued under Section 10(b) and Rule 10b–5 (and Section 20(a) against Sung), alleging material misrepresentations/omissions and scienter; the district court dismissed claims against Sung and Frazer for failure to plead scienter with particularity under the PSLRA.

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Whether plaintiffs sufficiently pled a material misrepresentation/omission and scienter against CFO Elsa Sung for overstating cash balances	Sung certified filings and reassured investors; magnitude of alleged overstatement, internal-control red flags, SEC investigation, resignation, and obstruction support strong inference of scienter	No particularized facts showing Sung knew or was severely reckless; ambiguities about amounts, timing, and her knowledge; residence in U.S. separate from China; no insider trading or profiting	Court: Dismissed as to Sung — allegations insufficient to plead a strong inference of scienter (PSLRA/Tellabs standard)
Whether the alleged Hilead related-party transfer was a material omission giving rise to liability	The RMB 200M transfer to Hilead (chairman-controlled) was material and should have been disclosed; omission supports scienter	Complaint fails to allege when the transfer occurred or tie it to filings/duty to disclose	Court: Dismissed — timing and duty-to-disclose not pleaded; cannot rely on Hilead transaction to infer scienter
Whether auditor Frazer acted with scienter by issuing an unqualified audit	Frazer’s unqualified audit and later withdrawal support inference it knew of overstatements/internal-control failures	Auditor relied on client information; audit preceded many alleged red flags; no particularized allegations of audit deficiencies or intent	Court: Dismissed as to Frazer — complaint fails to plead audit so deficient that it amounted to no audit or that Frazer acted with intent/severe recklessness
Standard for pleading scienter in securities fraud (PSLRA application)	Plaintiffs argue circumstantial facts collectively create a cogent, strong inference of scienter	Defendants emphasize need for particularized facts and plausible nonculpable explanations under Tellabs	Court: Applied Tellabs/PSLRA; opposing nonculpable inferences (e.g., resignation for family reasons, limited ties to China, timing gaps) outweighed plaintiffs’ allegations

Key Cases Cited

Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (establishes that a complaint survives only if an inference of scienter is at least as cogent as any opposing inference)
Mizzaro v. Home Depot, Inc., 544 F.3d 1230 (lists elements of a Section 10(b) claim and PSLRA pleading requirements)
Thompson v. RelationServe Media, Inc., 610 F.3d 628 (scienter requires intent to deceive or severe recklessness)
Piedmont Office Realty Trust, Inc. v. XL Specialty Ins. Co., 769 F.3d 1291 (Federal Rule 12(b)(6) review standard)
In re Worlds of Wonder Secs. Litig., 35 F.3d 1407 (auditor scienter standard: audit so deficient it was no audit or egregious refusal to see the obvious)
Bryant v. Avado Brands, Inc., 187 F.3d 1271 (negligence alone insufficient to establish scienter)